This article was originally published in The Gray Sheet
FDA recalls Nebion's HLX-8 magnetic resonance device, which the company claimed can treat medical conditions such as cancer, carpel tunnel syndrome, migraines, arthritis and certain injuries, but is not FDA approved. Nebion "failed to provide FDA with any evidence to support these claims," FDA writes in an Oct. 3 Class I recall notice. On July 2, Nebion notified customers about the recall and instructed them to stop using the device and to report any adverse reactions or problems to FDA
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.